Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is attractive because its lead asset OV329 targets the clinically validated GABA-AT mechanism while seeking to avoid vigabatrin’s retinal toxicity, a key limitation that has historically constrained use despite proven anti-seizure efficacy. Its Phase 1 data in 68 healthy volunteers showed clean ophthalmology findings across five modalities, no treatment-related serious adverse events, and cortical inhibition stronger than historical vigabatrin at 400-600x lower doses, supporting a wider therapeutic index and meaningful commercial potential in refractory focal seizures, TSC, and infantile spasms. The balance sheet also supports execution, with $169.8M in cash, cash equivalents, and marketable securities as of June 30, 2026, funding operations into 2029 while multiple catalysts are expected from YE 2026 through H2 2027.

Ovid Therapeutics is viewed negatively because its lead vigabatrin-class exposure carries a meaningful ocular safety risk: the drug accumulates in the retina, can raise retinal GABA levels about 3x, and in rats the retina can hold roughly 18-20x more drug than brain, raising the odds of toxicity and clinical failure. The bear case further implies that even with a 20% probability of success across all three indications and a 12% discount rate, no pipeline value survives, with the $0.58 bear value reflecting only FY27 net cash and exercise proceeds. The KCC2 program OV4071 is carried at nil, underscoring the view that the company is more a cash shell than a durable, de-risked biotech franchise.